913 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
3 Big Pharma Stocks to Buy Right Now http://www.zacks.com/stock/news/429850/3-big-pharma-stocks-to-buy-right-now?cid=CS-ZC-FT-429850 Jun 14, 2019 - These big pharma stocks all have a Zacks Rank #2 or better.
Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod http://www.zacks.com/stock/news/429560/pharma-stock-roundup-mrk-buys-small-cancer-biotech-rhhby-mrk-drugs-get-fda-nod?cid=CS-ZC-FT-429560 Jun 14, 2019 - Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.
Alkermes Initiates Monothearpy Expansion Phase of ALKS 4230 http://www.zacks.com/stock/news/429125/alkermes-initiates-monothearpy-expansion-phase-of-alks-4230?cid=CS-ZC-FT-429125 Jun 13, 2019 - Alkermes (ALKS) initiates monotherapy expansion phase of ALKS 4230 to treat patients with renal cell carcinoma or melanoma.
Novartis Reports Data on Cosentyx for Psoriatic Arthritis http://www.zacks.com/stock/news/428752/novartis-reports-data-on-cosentyx-for-psoriatic-arthritis?cid=CS-ZC-FT-428752 Jun 12, 2019 - Novartis (NVS) announces new data on psoriatic arthritis drug, Cosentyx.
Merck's Keytruda Wins FDA Nod for First-Line Head/Neck Cancer http://www.zacks.com/stock/news/428338/mercks-keytruda-wins-fda-nod-for-first-line-head-neck-cancer?cid=CS-ZC-FT-428338 Jun 12, 2019 - Merck's (MRK) Keytruda is already approved for use in 15 cancer indications across 10 different tumor types in the United States.
Boost Your Portfolio's Health With These 3 Big Drug Stocks http://www.zacks.com/stock/news/428332/boost-your-portfolios-health-with-these-3-big-drug-stocks?cid=CS-ZC-FT-428332 Jun 12, 2019 - The large-cap pharma industry is doing well in 2019. Here are three stocks from the space that investors may consider betting on.
Lilly Announces Tradjenta Cardiovascular Outcome Study Data http://www.zacks.com/stock/news/427738/lilly-announces-tradjenta-cardiovascular-outcome-study-data?cid=CS-ZC-FT-427738 Jun 11, 2019 - Tradjenta leads to fewer events of hypoglycemia and modest weight reduction in type II diabetes patients compared to Sanofi's Amaryl.
Merck (MRK) to Buy Private Biotech Tilos for Up to $773M http://www.zacks.com/stock/news/427724/merck-mrk-to-buy-private-biotech-tilos-for-up-to-%24773m?cid=CS-ZC-FT-427724 Jun 11, 2019 - Merck (MRK) set to buy private preclinical biotech Tilos Therapeutics in a deal that could be worth up to $773 million
Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache http://www.zacks.com/stock/news/426292/pharma-stock-roundup-asco-update-fda-nod-for-llys-emgality-for-cluster-headache?cid=CS-ZC-FT-426292 Jun 07, 2019 - Pharma bigwigs present data from cancer studies at ASCO. Lilly's (LLY) CGRP Emgality gets FDA approval for episodic cluster headache in adults.
Dow 30 Stock Roundup: UNH to Hike Dividend, MRK Zerbaxa's New Indication Gets FDA Nod http://www.zacks.com/stock/news/426097/dow-30-stock-roundup-unh-to-hike-dividend-mrk-zerbaxas-new-indication-gets-fda-nod?cid=CS-ZC-FT-426097 Jun 07, 2019 - The index enjoyed a week of strong gains after the Fed Chair indicated that a near-term rate cut was increasingly likely.

Pages: 123456789101112...92

<<<Page 7>